Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer.
Colorectal cancer
HER2
Liver metastasis
Tumor heterogeneity
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
22 Jun 2024
22 Jun 2024
Historique:
received:
10
04
2024
accepted:
04
06
2024
medline:
23
6
2024
pubmed:
23
6
2024
entrez:
22
6
2024
Statut:
epublish
Résumé
HER2-targeted therapies have recently emerged as an option in the management of metastatic colorectal cancer (mCRC) overexpressing HER2. However, data regarding HER2 status in primary CRC and its corresponding liver metastases are limited, potentially influencing clinical decisions. Therefore, the aim of this study was to compare the HER2 status in primary CRC and paired liver metastases. Patients with mCRC who were operated from their primary colorectal cancer and their corresponding synchronous or metachronous liver metastases, in the digestive surgery department of Besançon University Hospital, between April 1999 and October 2021, were included. Tissue microarrays were constructed from matched primary CRC and liver metastastic tissue samples. HER2 status was assessed by immunohistochemistry and in situ hybridization according to Valtorta's criteria. A series of 108 paired primary CRC and liver metastases, including a series of multiple liver metastases originating from the same patients (n = 24), were assessed. Among the primary CRC, 89 (82.4%), 17 (15.8%) and 2 (1.8%) cases were scored 0, 1 + and 2 + respectively. In liver metastases, 99 (91.7%), 7 (6.5%) and 2 (1.8%) were scored 0, 1 + and 2, respectively. Overall, there was a 19% discrepancy rate in HER2 status between primary CRC and metastases, which increased to 21% in cases with multiple synchronous or metachronous liver metastases in a given patient. No significant difference was found between metachronous and synchronous metastases regarding the HER2 status (p = 0.237). Our study highlights the temporal and spatial heterogeneity of HER2 status between primary CRC and corresponding liver metastases. These findings raise the question of a sequential evaluation of the HER2 status during disease progression, to provide the most suitable treatment strategy.
Sections du résumé
BACKGROUND
BACKGROUND
HER2-targeted therapies have recently emerged as an option in the management of metastatic colorectal cancer (mCRC) overexpressing HER2. However, data regarding HER2 status in primary CRC and its corresponding liver metastases are limited, potentially influencing clinical decisions. Therefore, the aim of this study was to compare the HER2 status in primary CRC and paired liver metastases.
METHODS
METHODS
Patients with mCRC who were operated from their primary colorectal cancer and their corresponding synchronous or metachronous liver metastases, in the digestive surgery department of Besançon University Hospital, between April 1999 and October 2021, were included. Tissue microarrays were constructed from matched primary CRC and liver metastastic tissue samples. HER2 status was assessed by immunohistochemistry and in situ hybridization according to Valtorta's criteria.
RESULTS
RESULTS
A series of 108 paired primary CRC and liver metastases, including a series of multiple liver metastases originating from the same patients (n = 24), were assessed. Among the primary CRC, 89 (82.4%), 17 (15.8%) and 2 (1.8%) cases were scored 0, 1 + and 2 + respectively. In liver metastases, 99 (91.7%), 7 (6.5%) and 2 (1.8%) were scored 0, 1 + and 2, respectively. Overall, there was a 19% discrepancy rate in HER2 status between primary CRC and metastases, which increased to 21% in cases with multiple synchronous or metachronous liver metastases in a given patient. No significant difference was found between metachronous and synchronous metastases regarding the HER2 status (p = 0.237).
CONCLUSIONS
CONCLUSIONS
Our study highlights the temporal and spatial heterogeneity of HER2 status between primary CRC and corresponding liver metastases. These findings raise the question of a sequential evaluation of the HER2 status during disease progression, to provide the most suitable treatment strategy.
Identifiants
pubmed: 38909265
doi: 10.1186/s13000-024-01508-y
pii: 10.1186/s13000-024-01508-y
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
88Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–91.
doi: 10.1136/gutjnl-2015-310912
pubmed: 26818619
Imai K, Adam R, Baba H. How to increase the resectability of initially unresectable colorectal liver metastases: A surgical perspective. Ann Gastroenterol Surgery. 2019;3:476–86.
doi: 10.1002/ags3.12276
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10–32.
doi: 10.1016/j.annonc.2022.10.003
pubmed: 36307056
Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
doi: 10.1016/S0140-6736(10)61121-X
pubmed: 20728210
Alsina M, Arrazubi V, Diez M, Tabernero J. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. 2023;20:155–70.
doi: 10.1038/s41575-022-00703-w
pubmed: 36344677
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518–30.
doi: 10.1016/S1470-2045(18)30904-5
pubmed: 30857956
pmcid: 6781620
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–46.
doi: 10.1016/S1470-2045(16)00150-9
pubmed: 27108243
Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D’Andre S, et al. Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2/3 mutations: results from the TAPUR study. JCO Precis Oncol. 2022;6:e2200306.
doi: 10.1200/PO.22.00306
pubmed: 36315917
Nakamura Y, Okamoto W, Sawada K, Komatsu Y, Kato K, Taniguchi H, et al. TRIUMPH Study: A multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer (EPOC1602). Ann Oncol. 2017;28:v207.
doi: 10.1093/annonc/mdx393.137
Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24:496–508.
doi: 10.1016/S1470-2045(23)00150-X
pubmed: 37142372
Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22:779–89.
doi: 10.1016/S1470-2045(21)00086-3
pubmed: 33961795
Raghav KPS, Siena S, Takashima A, Kato T, Van Den Eynde M, Di Bartolomeo M, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. JCO. 2023;41:3501–3501.
doi: 10.1200/JCO.2023.41.16_suppl.3501
Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28:1481–91.
doi: 10.1038/modpathol.2015.98
pubmed: 26449765
Fujii S, Magliocco AM, Kim J, Okamoto W, Kim JE, Sawada K, et al. International harmonization of provisional diagnostic criteria for ERBB2-amplified metastatic colorectal cancer allowing for screening by next-generation sequencing panel. JCO Precis Oncol. 2020;4:6–19.
doi: 10.1200/PO.19.00154
pubmed: 35050726
Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2014;27:4–18.
doi: 10.1038/modpathol.2013.103
pubmed: 23807776
Creemers A, ter Veer E, de Waal L, Lodder P, Hooijer GKJ, van Grieken NCT, et al. Discordance in HER2 status in gastro-esophageal adenocarcinomas: a systematic review and meta-analysis. Sci Rep. 2017;7:3135.
doi: 10.1038/s41598-017-03304-9
pubmed: 28600510
pmcid: 5466678
Lee W-S, Park YH, Lee JN, Baek J-H, Lee T-H, Ha SY. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med. 2014;3:674–80.
doi: 10.1002/cam4.228
pubmed: 24668895
pmcid: 4101759
Styczen H, Nagelmeier I, Beissbarth T, Nietert M, Homayounfar K, Sprenger T, et al. HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. Oncotarget. 2015;6:15065–76.
doi: 10.18632/oncotarget.3527
pubmed: 25915155
pmcid: 4558136
Shan L, Lv Y, Bai B, Huang X, Zhu H. Variability in HER2 expression between primary colorectal cancer and corresponding metastases. J Cancer Res Clin Oncol. 2018;144:2275–81.
doi: 10.1007/s00432-018-2744-z
pubmed: 30203148
Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Machida E, et al. A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer. Br J Cancer. 2023;129:1176–83.
doi: 10.1038/s41416-023-02382-z
pubmed: 37543670
Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29:1108–19.
doi: 10.1093/annonc/mdy100
pubmed: 29659677
pmcid: 5961091
Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238:562–70.
doi: 10.1002/path.4679
pubmed: 26690310
pmcid: 4785607
Chen P-C, Yeh Y-M, Chu C-T, Su P-F, Chiu P-H, Lin B-W, et al. HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study. Eur J Cancer. 2023;181:62–9.
doi: 10.1016/j.ejca.2022.12.019
pubmed: 36640475
Babkoff A, Zick A, Hubert A, Tarantino P, Grinshpun A. Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future. ESMO Gastrointestinal Oncology. 2024;3. Available from: https://www.esmogastro.org/article/S2949-8198(23)00047-X/fulltext . Cited 2024 May 30.
Evrard C, Messina S, Sefrioui D, Frouin É, Auriault M-L, Chautard R, et al. Heterogeneity of mismatch repair status and microsatellite instability between primary tumour and metastasis and its implications for immunotherapy in colorectal cancers. Int J Mol Sci. 2022;23:4427.
doi: 10.3390/ijms23084427
pubmed: 35457245
pmcid: 9032866
Bhullar DS, Barriuso J, Mullamitha S, Saunders MP, O’Dwyer ST, Aziz O. Biomarker concordance between primary colorectal cancer and its metastases. EBioMedicine. 2019;40:363–74.
doi: 10.1016/j.ebiom.2019.01.050
pubmed: 30733075
pmcid: 6413540
Cremolini C, Rossini D, Dell’Aquila E, Lonardi S, Conca E, Del Re M, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan. JAMA Oncol. 2019;5:343–50.
doi: 10.1001/jamaoncol.2018.5080
pubmed: 30476968